Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), explains why a section on chronic kidney disease (CKD) management was added to the ADA's 2022 standard of care guidelines.
Transcript:
What evidence led to the addition of Section 11 in the ADA’s 2022 guidelines?
Gabbay: [A couple] of the things that became clear based on some of the recent studies and new treatments that are available are a couple of things. One, we know that chronic kidney disease continues to be a huge issue and it's under-diagnosed and under-treated. And second, we now have new treatments that can really lower the risk of chronic kidney disease, and particularly the progression. So, we called out all of that information by making chronic kidney disease a separate section [of the guidelines] to emphasize the importance of it.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More